ERBB2 and lung cancer: Another patient with ERBB2 IHC (1+) was found with an ERBB2-P780_Y781insGSP mutation, the third most common HER2 exon 20 insertions in lung cancer [17], which indicated that anti-Her2 therapies such as neratinib and trastuzumab ado-trastuzumab emtansine (T-DM1) might benefit patients.